Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after ...
- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb - - BMS-986249 Phase 2 study ongoing - SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, to...
- Presentation at World ADC Conference in San Diego - - CX-2051 integrates CytomX core platform expertise to potentially maximize therapeutic window - SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the ...
CytomX Therapeutics, Inc. (CTMX) Q2 2022 Earnings Conference Call August 04, 2022 05:00 PM ET Company Participants Chau Cheng - Vice President of Investor Relations & Corporate Communications Sean McCarthy - Chief Executive Officer & Chairman Carlos Campo...
Image source: The Motley Fool. CytomX Therapeutics (NASDAQ: CTMX) Q2 2022 Earnings Call Aug 04, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: CytomX Therapeutics (CTMX) Q2 2022 Earnings Call Transcript
CytomX press release ( NASDAQ: CTMX ): Q2 GAAP EPS of -$0.37 misses by $0.02 . Revenue of $18.17M (+11.5% Y/Y) misses by $0.21M . For further details see: CytomX GAAP EPS of -$0.37 misses by $0.02, revenue of $18.17M misses by $0.21M
- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 - - New INDs for two next-generation product candidates anticipated in 2023 - - Continued progress with...
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will virtually p...
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022, after ...
CytomX Therapeutics ( NASDAQ: CTMX ) on Wednesday announced strategic actions that are expected to extend the company's cash runway into 2025, including a reduction in its workforce by about 40%. CTMX said it would focus its internal efforts on its wholly-owned therapies, ...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...